期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
乳头状甲状腺癌与促甲状腺激素受体第三胞内环基因突变的研究
1
作者 蓝薇 张帆 +1 位作者 戴亚丽 于洁 《齐齐哈尔医学院学报》 2006年第8期899-900,共2页
目的探讨乳头状甲状腺癌的发病是否与促甲状腺激素受体(TSHR)第3胞内环基因突变相关。方法采用多聚酶联反应-单链构象多态性分析(PCR-SSCP)和DNA测序方法,对65例乳头状甲状腺癌和44例正常甲状腺组织TSHR第3胞内环基因进行检测。结果经PC... 目的探讨乳头状甲状腺癌的发病是否与促甲状腺激素受体(TSHR)第3胞内环基因突变相关。方法采用多聚酶联反应-单链构象多态性分析(PCR-SSCP)和DNA测序方法,对65例乳头状甲状腺癌和44例正常甲状腺组织TSHR第3胞内环基因进行检测。结果经PCR-SSCP检测乳头状甲状腺癌促甲状腺激素受体(TSHR)第3胞内环未发现明显带型异常;取2例对照组织和3例甲状腺癌组织进行DNA测序,TSHR2000位点碱基均由C→T,使得所编码的601位氨基酸由组氨酸(CAT)→酪氨酸(TAT)突变(His→Tyr),余未发现其他基因突变。结论乳头状甲状腺癌发病与TSHR第3胞内环基因突变无关;中国人TSHR基因与国外人群存在多态性差异。 展开更多
关键词 乳头状甲状腺甲状腺激素受体基因突变 单链构象多态性性分析
下载PDF
G蛋白偶联受体48与肿瘤发生发展关系的研究进展
2
作者 彭契六 朱春玲 《医学综述》 CAS 2021年第17期3419-3423,共5页
G蛋白偶联受体(GPCR)48属于GPCR家族,参与机体内多种生理反应的调节。随着对GPCR48研究的深入发现,其不仅在正常生长发育过程中发挥关键作用,而且还与肿瘤的发生、发展密切相关。GPCR48在多种肿瘤组织中为促癌受体,抑制肿瘤细胞中的GPC... G蛋白偶联受体(GPCR)48属于GPCR家族,参与机体内多种生理反应的调节。随着对GPCR48研究的深入发现,其不仅在正常生长发育过程中发挥关键作用,而且还与肿瘤的发生、发展密切相关。GPCR48在多种肿瘤组织中为促癌受体,抑制肿瘤细胞中的GPCR48表达可延缓肿瘤细胞的生长及转移,是一种潜在的肿瘤治疗分子靶点。然而,GPCR48在肿瘤中的作用机制非常复杂,目前尚未明确。因此,深入研究GPCR48的表达及调控相关机制对肿瘤的诊断、治疗及预后具有重要意义。 展开更多
关键词 肿瘤 G蛋白偶联受体48 G蛋白偶联受体家族 促癌受体
下载PDF
Effects of gastrin 17 on β-catenin/Tcf-4 pathway in Colo320WT colon cancer cells 被引量:5
3
作者 Jun Cao Jie-Ping Yu +2 位作者 Chao-Hong Liu Lan Zhou Hong-Gang Yu 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第46期7482-7487,共6页
AIM: To explore the effect of gastrin 17 (G17) on β-catenin/T cell factor-4 (Tcf-4) signaling in colonic cancer cell line Colo320WT. METHODS: The pCR3.1/GR plasmid, which expresses gastrin receptor, cholecystok... AIM: To explore the effect of gastrin 17 (G17) on β-catenin/T cell factor-4 (Tcf-4) signaling in colonic cancer cell line Colo320WT. METHODS: The pCR3.1/GR plasmid, which expresses gastrin receptor, cholecystokinin-2 receptor (CCK-2R), was transfected into a colonic cancer cell line Colo320 by Lipofectamine ^TM 2000 and the stably expressing CCK-2R clones were screened by G418. The expression levels of gastrin receptor in the Colo320 and the transfected Colo320WT cell line were assayed by RTPCR. Colo320WT cells were treated with G17 in a time-dependent manner (0, 1, 6, 12, 24 and 48 h), then with L365,260 (Gastrin17 receptor blocker) for 30 rain, and with G17 again for 12 h or L365,260 for 12 h. Expression levels of β-catenin in a TX-100 soluble fraction and TX-100 insoluble fraction of Colo320WT cells treated with G17 were detected by co-immuniprecipation and Western blot. Immunocytochemistry was used to examine the distribution of β-catenin in CoLoWT320 cells. Expression levels of c-myc and cyclin D1 in Colo320WT cells treated with G17 were assayed by Western blot. RESULTS: Expression levels of β-catenin in the TX-100 solution fraction decreased apparently in a time- dependent fashion and reached the highest level after G17 treatment for 12 h, while expression levels of β-catenin in the TX-100 insoluble fraction were just on the contrary. Immunocytochemistry showed that β-catenin was translocated from the cell membranes into the cytoplasm and nucleus under G17 treatment. Expression levels of c-myc and cyclin D1 in the G17- treated Colo320WT cells were markedly higher compared to the untreated Colo320WT cells. In addition, the aforementioned G17-stimulated responses were blocked by L365,260.CONCLUSION: Gastrin17 activates β-catenin/Tcf-4 signaling in Colo320WT cells, thereby leading to over- expression of c-myc and cyclin D1. 展开更多
关键词 Gastrin17 Cholecystokinin-2 receptor Colorectal carcinoma β-catenin/Tcf-4 pathway
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部